Comparative In silico evaluation of c-Abl inhibitors for Parkinson's disease therapy
Biochemical and Biophysical Research Communications · 2026
DOI: 10.1016/j.bbrc.2025.153175 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Devu B Kumar und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Biology, Indian Institutes of Science Education and Research-Thiruvananthapuram, Kerala, India. Hauptthemen laut MEDLINE: Parkinson Disease, Proto-Oncogene Proteins c-abl, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Indian Institute of Science Education and Research Thiruvananthapuram, Science and Engineering Research Board.
Abstract (Originalsprache)
Parkinson's disease (PD), the second most common neurodegenerative disorder, is characterized by the dopaminergic neuronal loss in the substantia nigra and progressive motor deficits. The non-receptor tyrosine kinase c-Abl is aberrantly activated in PD brains and contributes to α-synuclein pathology, making it an attractive therapeutic target. Although several c-Abl inhibitors have shown neuroprotective effects in preclinical models, most fail in clinical trials due to poor pharmacokinetic profiles and limited brain penetration. Here, we performed a comparative in silico evaluation of five c-Abl inhibitors-Imatinib, Nilotinib, Ponatinib, Risvodetinib, and PD180970. Binding affinity, target specificity, physicochemical and pharmacokinetic properties, blood-brain barrier permeability, and toxicity profiles were systematically assessed and cross-validated. Molecular docking studies revealed that PD180970 exhibited the strongest binding affinity for the kinase domains of both human and mouse c-Abl. To validate these findings, we performed molecular dynamics (MD) simulations and analyzed root mean square deviations (RMSD), root mean square fluctuation (RMSF), hydrogen bonding, and radius of gyration of ligands, which confirmed the superior stability and binding of PD180970. Target prediction analysis indicated that PD180970 and Ponatinib had the highest selectivity with minimal off-target hits. SwissADME profiling further showed that PD180970 possesses favorable pharmacokinetic characteristics. The BBB permeability and toxicity analysis, using ADMETLab and DeepPK, predicted that PD180970 has enhanced blood-brain barrier permeability and a lower toxicity profile compared to the other inhibitors. Together, these integrated computational findings indicate PD180970 as a promising next-generation c-Abl inhibitor and support its prioritisation for further preclinical and clinical studies in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biology, Indian Institutes of Science Education and Research-Thiruvananthapuram, Kerala, India.
- School of Biology, Indian Institutes of Science Education and Research-Thiruvananthapuram, Kerala, India. Electronic address: poonam@iisertvm.ac.in.
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India
- Indian Institute of Science Education and Research Thiruvananthapuram
- Science and Engineering Research Board
Zitieren
APA
Kumar, D. B., Subramanya, S. K., & Thakur, P. (2026). Comparative In silico evaluation of c-Abl inhibitors for Parkinson's disease therapy. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2025.153175
Vancouver
Kumar DB, Subramanya SK, Thakur P. Comparative In silico evaluation of c-Abl inhibitors for Parkinson's disease therapy. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2025.153175
BibTeX
@article{Kumar2026,
author = {Kumar, Devu B and Subramanya, Santhosh Kumar and Thakur, Poonam},
title = {Comparative In silico evaluation of c-Abl inhibitors for Parkinson's disease therapy},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
doi = {10.1016/j.bbrc.2025.153175}
}
EUVIMED